Somapacitan Once a Week with Daily Norditropin® in Children Who Need Help to Grow
Full IRB Study Title:
A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature
IRB Study ID: 2023-055
For complete details, please view the study on Clinicaltrials.gov
Study Sponsor:
NovoNordisk A/S
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
JoAnn Katz, BSN, RN, CCRC
(330)543-0690
Who May Qualify:
For complete details, please view the study on Clinicaltrials.gov
Who Does NOT Qualify:
For complete details, please view the study on Clinicaltrials.gov
Lead Investigator
Naveen Uli, MD
Medical Director, Center for Diabetes and Endocrinology; Pediatric Endocrinologist
